Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Trial Profile

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Antiandrogens (Primary) ; Celecoxib (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Estradiol (Primary) ; Metformin (Primary) ; Zoledronic acid (Primary) ; Prednisolone; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAMPEDE
  • Most Recent Events

    • 23 Mar 2018 Planned number of patients changed from 8100 to 11200.
    • 26 Feb 2018 Results (n=566; data cut-off date: 10 Feb 2017) of randomized comparative analysis of two new treatment standards for hormone-naive prostate cancer (standard of care+abiraterone acetate with prednisolone vs standard of care + docetaxel with prednisolone) published in the Annals of Oncology Journal.
    • 10 Feb 2018 Results assessing impact of docetaxel on health related quality of life (HRQoL), resource use and cost-effectiveness for men treated in the STAMPEDE trial, were presented at the 2018 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top